Therefore, antibodies that are designed to target epitopes within the MUC1 core peptide or the altered glycopeptide epitopes are more likely to bind to tMUC1, and not to MUC1, on normal cells, thus rendering them an attractive candidate molecule for cancer-specific immunotherapies [18]. The gene discussed is MUC1; the disease is cancer.